strong>Aduro Biotech Inc., of Berkeley, Calif., said an investigator-sponsored phase II trial is under way to evaluate its immuno-oncology product candidates Gvax Pancreas and CRS-207 in combination with Opdivo (nivolumab), a monoclonal antibody against programmed death-1 receptor, or PD-1, developed by Bristol-Myers Squibb Co., of New York.